CORAL GABLES, FL / ACCESSWIRE / October 5, 2017 / Investors are looking to the most recent reports on United States initial jobless claims and trade balance, which were scheduled to be announced today, Thursday morning. Market participants are also watching for the latest U.S. factory orders data, also set to be released this morning. Two industries in focus during Thursday’s trading session are biotech and technology, following Google’s unveiling of its new Google Pixel 2 smartphones and a continued uptrend across the entire biotech sector. With that being said, here are three companies that are trending during Thursday morning’s trading session.
Lexington Biosciences, Inc. (LXGTF), a development stage medical device company that operates within the healthcare industry, has seen an increase in trading volume over the course of this trading week. On Wednesday (10/4/17), the stock recorded its highest volume day of the year. Since Monday’s trading session (10/2/17), the stock’s price per share has gained 19.94% from lows of $0.2918 on Monday to daily highs during Thursday morning’s trading session of $0.35. For More Info, Click Here.
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, saw a price per share jump of 65.94% from Wednesday’s (10/4/17) closing price of $2.32 to intraday highs during Thursday’s trading session of $3.85. The company recently announced on Monday (10/2/17) that the company presented new information on its proprietary next-generation ADAPTIR™ protein therapeutic platform at the Bispecific Summit.
“Our data on APVO436 confirms the important advances we have made with our next generation ADAPTIR candidates, specifically improved stability, half-life, activity and manufacturability – all critical attributes for commercialization,” stated Jane Gross, Ph.D., Senior Vice President and Chief Scientific Officer. For More Info, Click Here.
MannKind Corp (NASDAQ: MNKD) has been on an uptrend since the start of the trading week. During Thursday morning’s trading session, the stock hiked 16.02% from lows of $3.62 to daily highs of $4.20. The company announced earlier in the week that the FDA approved its new label update on its insulin drug, Afrezza. For More Info, Click Here.
“Available data suggests approximately 70% of people living with diabetes on insulin are not at HbA1c goals of <7% ²,” stated Michael Castagna, Chief Executive Officer, MannKind Corporation. “We firmly believe that in order for patients to achieve better HbA1c goals, control of mealtime glucose spikes is critical. This label update supports Afrezza as a unique fast-acting mealtime insulin that provides doctors and patients with the flexibility necessary to help them achieve glycemic control.”
TECHSTOCKINSIDER.com is owned by MIDAM VENTURES LLC, a Florida Corporation that has been compensated $100,000 by Ellis Stewart, LLC for a period beginning October 1, 2017 and ending November 1, 2017 to publicly disseminate information about Lexington Biosciences, Inc. (LXGTF). Full Disclaimer Here.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TSI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://TechStockInsider.com.
TSI, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com